INVO Bioscience touts South American infertility treatment trial results

February 5, 2010 by MassDevice staff

Infertility treatment device maker INVO Bioscience says its INVOcell incubation device posted a 36 percent success rate in a South American clinical trial.

INVO Bioscience (OTC:IVOB) is touting the results of a South American clinical trial it says showed its INVOcell, a small capsule used to incubate eggs and sperm as an alternative to conventional infertility treatments, posted a 36 percent success rate in impregnating infertile women.

The Beverly, Mass.-based company said more than two-thirds of the 50 patients enrolled at the Center of Fertility and Sterility in Bogota, Colombia, reached the study's endpoint of clinical pregnancy, defined as a fetal heartbeat at seven weeks. That success rate puts the technique on par with other infertility treatments, company officials said, but with a much lower multiple pregnancy rate of 6 percent.

IVOB also addressed several inquires it said it received regarding the sale of company stock by members of its management team. INVO, founded in 2007, went public in December 2009. That month the company announced an agreement with AGS Capital Group LLC allowing it to sell up to $10 million worth of its own stock in order to raise more funds. Last year, INVO Bioscience's employees deferred their pay in order to keep it afloat.

"Since the company became public on Dec. 6, 2009, the directors and officers of the company have sold only 30,000 shares of the 31.3 million shares they hold," according to a press release. "The officers have not taken salaries in the past year in order to preserve cash; however, the company continues to accrue the unpaid salaries."